Tilray Brands Inc

Tilray Brands Inc (TLRY) Stock Analysis

$3.270

-0.088 (-2.68%)At close

Loading chart…
High
3.385
Open
3.310
VWAP
3.30
Volume
4.10M
Mkt Cap
1.43B
Low
3.250
Amount
13.53M
EV/EBITDA, TTM
138.58

Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. It also owns digital healthcare and patient engagement platform, focused on medical cannabis education, physician consultations, and patient support services.

AI analysis of Tilray Brands Inc (TLRY)

Sell

Tilray Brands Inc is not a good buy right now due to significant financial losses and declining stock performance. The current price is $3.54, and the stock has dropped 63.58% year-to-date. Additionally, the RSI is at 26.854, indicating it is oversold, but this does not guarantee a price recovery in the near term.

Analyst Ratings (3)

+192.66% upside
Buy
3 Buy
0 Hold
0 Sell
Current: 3.27
Low
8.50
Average
9.57
High
10.00

TD Cowen

2026-07-14

Price Target

$5

Buy

Canaccord

2026-04-02

Price Target

$13

Hold

Roth Capital

2026-04-01

Price Target

$10

Buy

Alliance Global

2026-04-01

Price Target

$7

Neutral

TD Cowen

2026-03-30

Price Target

$7

Buy

Valuation Metrics

The current forward P/E ratio for Tilray Brands Inc (TLRY) is 1000.00, compared to its 5-year average forward P/E of 152.40.

Forward P/E

Strongly Overvalued
5Y Average P/E
152.40
Current P/E
1000.00
Overvalued
548.70
Undervalued
-243.89

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
24.69
Current EV/EBITDA
138.58
Overvalued
46.08
Undervalued
3.29

Forward P/S

Undervalued
5Y Average P/S
2.14
Current P/S
0.43
Overvalued
3.84
Undervalued
0.45

Alphio AI Price Scenarios for TLRY

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TLRY

$0.55

Scenario price

B

Base

Base · 50%TLRY

$0.49

Scenario price

B

Bear

Bear · 25%TLRY

$0.44

Scenario price

Events Timeline

2026-10-08 (ET)

16:30:00

Major Averages Decline Amid Rising Oil Prices

12:30:00

Major Averages Decline as Oil Prices Surge

09:00:00

Stock Futures Lower as Oil Prices and Treasury Yields Rise

07:30:00

Company Reaffirms FY2027 Adjusted EBITDA Expectation of $68M to $75M

07:30:00

Tilray Brands Reports Q1 Revenue of $257.15M

News

TLRY FAQ — answered by Alphio AI

Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. It also owns digital healthcare and patient engagement platform, focused on medical cannabis education, physician consultations, and patient support services. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Tilray Brands Inc is not a good buy right now due to significant financial losses and declining stock performance. The current price is $3.54, and the stock has dropped 63.58% year-to-date. Additionally, the RSI is at 26.854, indicating it is oversold, but this does not guarantee a price recovery in the near term.

3 analysts cover TLRY: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.57.

Community

More ↗
lunarviper23 hr. ago

$TLRY is moving forward with its strategic transformation. From expanding its diversified portfolio to improving operational efficiencies and pursuing new growth opportunities, Tilray Brands is laying the groundwork for a stronger future. Can these strategic moves support sustainable growth and drive the stock's next rally? What's your take?

Show more
lunarviper9/24/2026

🚀 $TLRY is moving into its next growth phase with a diversified push across cannabis, beverages, hospitality and wellness. 🌿🍺 Management is targeting $68M-75M in FY27 adjusted EBITDA, while BrewDog integration, international cannabis expansion and brand scaling remain key priorities. 💰 Tilray ended FY26 with about $235M in cash and securities and just $0.7M in net debt, giving it financial flexibility to keep investing in growth. 📈🔥

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started